Innovative treatments for the ocular surface

Article

Novel options now available should help with patient comfort

Treatment of ocular surface inflammation and dryness by warming the lids and applying gentle massage has been prescribed for years with variable results. Even when the technique is applied correctly and patients are actually able to devote enough time to it, some patients gain little more than temporary relief.

Easing the treatment regime

Development of this device coincides with a paradigm shift in treatment focus to meibomian gland obstruction and dysfunction as a key, limiting step leading to compromise of the ocular surface in the majority of cases of dysfunctional tear syndrome (DTS). Just as with any other new device, we approach implementation of these devices carefully and after they've been supported by clinical data demonstrating efficacy and safety.

In the journal Cornea,1 Steve Lane and colleagues compared LipiFlow to iHeat warm compress systems in a crossover, multicentre clinical trial in one hundred and thirtynine patients. At two weeks of treatment, the iHeat arm (n = 70) crossed over to LipiFlow (n = 69) treatment. After studying meibomian gland (MG) assessment, tear break up time (TBUT), and dry eye symptoms, LipiFlow treatment demonstrated statistically significant superiority at 2 and 4 weeks. Moreover, the crossover group showed a significant improvement two weeks post treatment with LipiFlow.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.